Efficacy Study of a Novel Skin Health Product to Reduce an UVB Induced Erythema

Launched by AMAZENTIS SA · Mar 19, 2022

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Written Informed Consent to participate in the study
• • Willingness to actively participate in the study and to come to the scheduled visits
• • Female and/or male
• • From 18 to 65 years of age
• • Uniform skin color and no erythema or dark pigmentation in the test area
• • ITA° \> 28 in the test area
• Exclusion Criteria:
• • Female subjects: Pregnancy or lactation
• • Drug addicts, alcoholics
• • AIDS, HIV-positive or infectious hepatitis
• • Conditions which exclude a participation or might influence the test reaction/evaluation
• • Participation or being in the waiting period after participation in cosmetic and/or pharmaceutical studies pertaining to the test area
• • One of the following illnesses with reduced physical capability/fitness: asthma (symptom-free allergic asthma is not an exclusion criterion), hypertension, cardiovascular diseases
• • Cancer not being diagnosed as cured and requiring chemotherapy, irradiation and/or hormonal treatment within the last 2 years
• • Insulin-dependent diabetes mellitus
• • Electronic implant (e.g. pace maker, insulin pump, hearing aid, and the like) that cannot be removed during irradiation
• • Documented allergies to cosmetic products and/or ingredients
• • Active skin disease at the test area
• • Irregularly tanned skin in the test area
• • Medical history of dysplastic nevi, melanoma or other skin carcinoma
• • Medical history of abnormal response to sunlight
• • Regular use of tanning beds (more than 10 times within the last 6 months)
• • Wounds, moles, tattoos, scars, irritated skin, excessive hair growth, etc. at the test area that could influence the investigation
• • Usage of medication with known photo-toxic and/or photo-sensitizing potential (e.g. some antibiotics, blood pressure regulating agents and antidepressants agents; hypericum perforatum) within the last 14 days prior to the start of the study and/or throughout the entire course of the study
• • Any topical medication at the test area within the last 7 days prior to the start of the study and/or throughout the entire course of the study
• • Systemic therapy with immuno-suppressive drugs (e.g. corticosteroids) and/or antihistamines (e.g. antiallergics) within the last 7 days prior to the start of the study and/or throughout the entire course of the study
• • Systemic therapy with anti-phlogistic agents or analgetics (e.g. diclophenac), except for minor pain relief medicine like acetylsalicylic acid or paracetamol within the last 3 days prior to the start of the study and/or throughout the entire course of the study